Table 2.
Results of multivariate analysis
| i. Analysis of diagnostic sample group | ii. Analysis of extended sample group | |||
|---|---|---|---|---|
| Samples—diagnostic | Samples—diagnostic, refractory, relapse | |||
| Predictors—gene mutations, leukemia-related and patient-related characteristics | Predictors—leukemia-related characteristics | |||
| Engraftment ability (categorical, engraftment Y/N) | Engrafted n = 21 | Engrafted n = 26 | ||
| Non-engrafted n = 18 | Non-engrafted n = 25 | |||
| Hotelling’s T-Squared test | Hotelling’s T-Squared test | |||
| No predictors identified | – | no predictors identified | – | |
| Engraftment intensity (continuous, percentage of hCD45+ cells) | Engrafted n = 21 | Engrafted n = 26 | ||
| General linear model | General linear model | |||
| Cytogenetic risk | p < 0.001 | Complex karyotype | p = 0.008 | |
| DNMT3A | p = 0.002 | BM blast % | p = 0.006 | |
| TET2 | p = 0.001 | CD33+ % | p = 0.04 | |
| NRAS (negative predictor) | p = 0.004 | |||
| BM blast % | p = 0.01 | |||
| Engraftment latency (categorical, engraftment at 12 or 16 weeks) | Engrafted n = 21 | Engrafted n = 26 | ||
| Hotelling’s T-Squared test | Hotelling’s T-Squared test | |||
| PB WBC + CD33+ % | p = 0.02 | PB blast % + CD33+ % | p = 0.01 | |
| PB WBC + FLT3-TKD | p < 0.05 | PB blast % + CD33+ % + BM blast % | p = 0.02 | |
| PB WBC + CEBPA double mutated | p < 0.05 | |||
| PB WBC + TET2 | p < 0.05 | |||
| PB WBC + SRSF2 | p < 0.05 | |||
| PB WBC + CD33+ % + Cytogenetic risk | p = 0.03 | |||
Association of AML sample characteristics (predictors) with three engraftment outcomes—engraftment ability (categorical), engraftment intensity (continuous), engraftment latency (categorical), was assessed. Hotelling’s T-Squared test was applied for categorical outcomes; we list all statistically significant combinations of two predictors plus the best fitting combination of three predictors. General linear model (GLM) was used to select the best-fit model for prediction of the continuous outcome, engraftment intensity; we list the prediction model with the highest AIC score and only statistically significant coefficients. The analyses were performed for the group of 47 diagnostic samples (on the left) and the extended group of all 68 samples from different disease stages (on the right). For the extended group, only the effect of leukemia-related characteristics was examined
BM Bone marrow, non-CN AML AML with cytogenetic aberrations other than complex karyotype, LEU leukocytes, n count, N negative, PB peripheral blood, WBC white blood count, Y positive